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SUMMARY 
 
Isoniazid forms part of the first line anti-tuberculosis therapy and it is generally used to treat 
latent Mycobacterium tuberculosis infection. Isoniazid inhibits synthesis of long chain 
mycolic acids found in cell wall of Mycobacterium tuberculosis, which have proven vital for 
the survival of the bacterium. Mycolic acids are primarily synthesized by the fatty acid 
synthase enzyme (FAS) system found in mycobacteria as the FAS-I and FAS-II complex. 
Isoniazid kills the bacteria by blocking the FAS-II complex, required for extension of 
mycolates. It does this by entering the tubercle bacilli as a prodrug where isoniazid becomes 
activated by catalase peroxidase encoded by katG gene. The activated isoniazid then forms a 
complex with NAD+ which targets InhA (NADH-dependent enoyl-acyl carrier protein 
reductase) located in the FAS-II complex. Loss of catalase peroxidase, due to gene mutations 
or a complete katG gene deletion is one of the primary mechanisms conferring resistance to 
INH in Mycobacterium tuberculosis. In addition, four other genes (inhA, KasA, ndh and 
ahpC) are also associated with INH resistance. Nonetheless, mutations in these five genes are 
present in only 70-80% of INH resistant clinical isolates, implying that other mechanisms are 
involved in resistance of Mycobacterium tuberculosis to isoniazid. 
This study aims to quantify the expression level of genes induced by isoniazid in the mycolic 
acid pathway and drug transport in two closely related Mycobacterium tuberculosis Beijing 
cluster 208 isolates. These are the fully susceptible (K636) and isoniazid mono-resistance 
strains (R55), with minimum inhibitory concentrations of 0.1 and 4 µg/ml, respectively. Both 
these isolate had no isoniazid gene associated mutations. The isolates were cultured in the 
presence and absence of 0.1µg/ml isoniazid for 24 hours after which RNA was extracted 
followed by QRT-PCR analysis to identify differentially expressed genes.  
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This result has shown that various genes were differentially expressed in response to low 
level INH exposure. The most significant up-regulation was observed in genes (acpM, fabD, 
Accd6 and fbpC) encoding the FAS-II complex and genes (efpA, iniA, iniB, and mmpl7) 
involved in drug transport. In addition, two genes (ndh and fbpC) were significantly down-
regulated in the isoniazid mono-resistant isolate. Based on these findings, we propose a 
model whereby isoniazid exposure in the susceptible isolate inhibits FAS-II complex and 
with its associated accumulation in mycolates kills the bacterium. In contrast, we propose that 
in the resistance isolate the bacterium acquires additional resistance by the activation of 
efflux pumps in combination with disruption in INH-NAD+ complex formation that protect 
inhibition of InhA located in FAS-II complex.   
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OPSOMMING 
 
Isoniasied vorm deel van die eerste linie van behandeling teen tuberkulose en word algemeen 
gebruik om latente Mycobacterium tuberculosis infeksie te behandel.  Isoniasied inhibeer die 
sintese van langketting mikolitiese sure wat in die selwand van Mycobacterium tuberculosis 
voorkom. Dit is bewys dat hierdie sure essensiëel is vir die oorlewing van die bakterie. 
Mikolitiese sure word hoofsaaklik gesintetiseer deur die vetsuur sintase ensiem (FAS) 
sisteem wat in mikobakterieë voorkom as die FAS-I en FAS-II komplekse. Isoniasied dood 
die bakterieë deur die FAS-II kompleks, wat nodig is om die verlenging van mikoliete, te 
blokkeer.  Dit word bewerkstellig deurdat „n pro-vorm van die middel die tuberkulose bacilli 
binnedring, waarna isoniasied geaktiveer word deur katalase peroksidase, wat deur die katG 
geen geënkodeer word. Die geaktiveerde isoniasied vorm „n kompleks met NAD+, wat InhA 
(NADH-afhanklike enoїasiel draer proteїenreduktase), geleë  in die FAS-II kompleks teiken.  
Een van die primêre meganismes wat weerstandigheid teen isoniasied bewerkstellig, is die 
verlies van katalase peroksidase weens geenmutasies of algehele delesie van die katG geen. 
„n verdere vier gene (inhA, kasA, ndh en ahpC) word ook verbind met isoniasied 
weerstandigheid. Nietemin is mutasies in hierdie vyf gene teenwoordig in slegs 70-80% van 
isoniasied weerstandige kliniese isolate, wat impliseer dat ander meganismes ook betrokke is 
in die weerstandigheid van Mycobacterium tuberculosis teen isoniasied. 
Die doel van hierdie studie is om die vlak van uitdrukking van gene wat deur isoniasied in die 
mikolitiese suur biochemiese pad geїnduseer word, asook middel transport te kwantifiseer in 
twee naby verwante Mycobacterium tuberculosis isolate van Beijing groep 208. Die twee 
isolate is die volledig sensitiewe (K636) en isoniasied monoweerstandige (R55), met 
minimum inhiberende konsentrasies van onderskeidelik 0.1 en 4µg/ml. Mutasies wat 
geassosiëer word met isoniasied weerstandigheid was afwesig in beide die isolate. Kulture is 
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van die isolate gemaak met en sonder 0.1µg/ml isoniasied vir 24 uur, waarna RNA 
geëkstraeer is deur middel van QRT-PCR analise om gene te identifiseer wat verskillend 
uitgedruk word. 
Die resultate toon dat verskeie gene verskillend uitgedruk is in reaksie op laevlak isoniasied 
blootstelling. Die mees prominente opregulering is waargeneem in die gene (acpM, fabD, 
accd6 en fbpC) wat die FAS-II kompleks enkodeer, asook die gene (efpA, iniA, iniB en 
mmpl7) wat betrokke is in middel transport.  Beduidende afregulering van „n verdere twee 
gene in die isoniasied monoweerstandige isolate, naamlik ndh en fbpC is waargeneem. Op 
grond van hierdie waarnemings, stel ons „n model voor waarvolgens isoniasied blootstelling 
in die sensitiewe isolaat die FAS-II kompleks inhibeer, en met die gevolglike akkumulasie 
van mikoliete, dood dit die bakterium. In teenstelling stel ons voor dat addisionele 
weerstandigheid bekom word in die weerstandige isolaat deur die aktivering van 
uitvloeipompe, in kombinasie met die ontwrigting van die INH-NAD+ kompleksvorming wat 
die inhibisie van InhA binne die FAS-II kompleks beskerm. 
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Chapter 1 
 
1.1 BACKGROUND 
 
Tuberculosis (TB), caused by an acid-fast bacillus Mycobacterium tuberculosis 
(M.tuberculosis) (18) leads to 1.7 million deaths annually (24,26). The global TB incidence is 
further aggravated by emergence of human immunodeficiency virus (HIV), which accounts 
for 15% of global TB burden (24). Although, the rate of TB incidence is slowly declining at 
less than 1% per year (26), African countries are still experiencing high burden of TB, fuelled 
by the high prevalence of HIV and an increase in population (24-26). Current evidence-based 
short course regimens of chemotherapy for TB have been effective in curing TB, especially 
under the management of Direct Observed Therapy, short course (DOTS) and its successor 
the STOP TB strategy (8,19,21). The main purpose of this strategy is to treat infected 
patients, prevent transmission and development of drug resistance TB (7). DOTS was 
implemented by the World health Organization (WHO) in the mid-1990‟s and was adopted in 
South Africa in 1996 (17,26). Since its implementation, treatment of smear positive cases 
reached the global target of 85% for the first time in 2007 (8,24-26).  
Streptomycin (STR) was the first effective anti-TB drug used for the treatment of TB. 
However soon after its introduction in 1944, resistance to the drug was observed in clinical 
isolates of M.tuberculosis (4,11). Resistance to anti-TB drugs in M.tuberculosis is due to 
spontaneous chromosomal mutations as genetic elements such as plasmids and transposons 
do not mediate drug resistance in pathogen (5,18,27). Subsequent spread of these resistant 
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M.tuberculosis strains from the index patients to others, exacerbate the resistant TB epidemic 
(23). 
More recently whole genome sequencing of various M.tuberculosis strains, including drug 
resistance strains, have been completed to further investigate the evolution of drug resistance 
(2,12). To date, a total of 14 genes were found to be associated with resistance to anti-TB 
drugs: isoniazid (INH) [katG, inhA, ndh, ahpC, and KasA],  rifampicin (RIF) [rpoB],  
pyrazinamide (PZA) [pncA], ethambutol (EMB) [embA, embB and embC], STR, capreomycin 
(CAP), kanamycin (KAN), amikacin (AMI) [rpsL and rrs] and fluoroquinolones (FQs) [gyrA 
and gyrB] (18,22). Recently a database was established listing mutations associated with 
M.tuberculosis drug resistance and frequencies of the most common mutation associated with 
resistance to specific drugs (20). 
M.tuberculosis strains, resistant to at least INH and RIF are defined as multi-drug resistant 
TB (MDR-TB) (3). Data collected over the past decade from over 100 countries indicate that 
5% of all TB cases have MDR-TB (26). The highest rate of MDR-TB recorded was 500 000 
in 2008, where 1 in 10 of MDR-TB was classified as extensively drug resistant (XDR-TB) 
(24,26).  XDR-TB is defined as an MDR isolate with additional resistance to one of the FQs 
and any one of the three injectable second line anti-TB drugs (KAN, AMI and CAP) (10,15). 
The emergence of MDR-TB and XDR-TB place additional pressure on TB control programs 
and introduce fears of TB epidemic turning into a drug resistance epidemic (6).  
INH was discovered in 1952, and still remains one of the forefront chemotherapeutic agents 
to fight TB (14). This is mainly due to its high activity against dividing M.tuberculosis (28). 
INH primarily targets the mycolic acid pathway and ultimately results in inhibition of 
biosynthesis of mycolic acids (13). Resistance of M.tuberculosis to INH is as results of 
various genomic mutations found in five genes (katG, inhA, kasA, ndh and ahpC)  (18). Most 
3 
 
 
prominent of these mutations is the S315T found in katG gene which is the major mechanism 
of INH resistance in M.tuberculosis and mutation in inhA gene or its promoter region found 
at position -15(C-T) (9,16).  However these resistance mutations have been found to be 
absent in approximately 20-30% of INH resistance clinical isolates (18). INH mono-
resistance or resistance in combination with other drugs is now the second most common type 
of resistance globally, accounting for 13% of all new and previously treated TB cases (1,26).  
  
1.2 PROBLEM STATEMENT: 
The mechanism of action of INH is still poorly defined and it is therefore important to further 
comprehend the protective mechanisms of M.tuberculosis against INH.  
 
1.3 OVERALL HYPOTHESIS: 
In this study we hypothesize that M.tuberculosis protects itself against INH by an interplay 
between intrinsic and extrinsic mechanism and also by detoxification of INH. 
 
1.4 AIMS OF THE STUDY: 
1. To quantify the expression level of genes induced by INH in the mycolic acid pathway in 
an INH susceptible and INH mono resistant M.tuberculosis Beijing strain genotype 
without any INH gene associated mutations. 
2. To investigate efflux pumps as an additional protective mechanism against INH. 
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1.5 EXPERIMENTAL APPROACH: 
 
Genotypically closely related Beijing cluster 208, INH susceptible (K636) and INH-mono 
resistant (R55) strain will be selected from an existing database at the University of 
Stellenbosch. The strains will be cultured in liquid medium to midlog phase and when the 
appropriate growth phase is reached, the cultures will then be incubated in the presence or 
absence of sub-lethal concentration of INH for 24hrs, after which RNA will be extracted. 
Expression quantification of candidate genes will be done by quantitative Real-Time PCR 
and data analyses will be done by means of REST program using the delta-delta Ct equation. 
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Chapter 2 
 
Mycobacterium tuberculosis protective mechanisms against isoniazid 
 
1. INTRODUCTION 
 
There are several mechanisms that confer bacterial resistance to antibiotic, resistance can be 
intrinsic where the cell envelope permeability and efflux pumps plays a major role by 
controlling the amount of antibiotic allowed to penetrate the cell wall (21,41,56). Another 
resistance mechanism is acquisition of mutations through selective pressure of antibiotics or 
uptake of genetic information from other bacteria through horizontal transfer (6,114). 
Mycobacterium tuberculosis (M.tuberculosis) has refined these resistant mechanisms to 
ensure optimal survival.  
The tubercle bacillus bases its pathogenicity on the ability to survive within the infected host 
by inhibiting phagolysosome biogenesis in microphages (46,78). A unique characteristic of 
M.tuberculosis is the ability to exist in a dormant state within infected tissue, where it can 
persist for several decades (39,64). This has been in part explained by the presence of the 
M.tuberculosis distinctive complex cell wall, which also plays a role in the growth and 
survival, low permeability to hydrophobic antibiotics, resistance to chemical injury, acid-base 
staining (12) and biofilm formation (95) of the bacterium (60,63).  
Isoniazid (INH) is the most effective and specific anti-TB drug used for treatment of TB, as it 
is used for treatment of latent M.tuberculosis infection and prevention of active disease and 
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subsequent transmission (36,137). It enters the tubercle bacillus by passive diffusion and 
primarily targets mycolic acid biosynthesis (5,82,98). It is then activated by catalase 
peroxidase encoded by katG gene to produce acyl radical-INH-NAD adduct (55). This in turn 
blocks the InhA (NADH-dependent enoyl-[acyl-carrier-protein]) reductase located in FAS-II 
complex (113), resulting in the accumulation of saturated fatty acids which leads to killing of 
M.tuberculosis (138).  
However the natural mutation rate of INH is higher than other anti-TB drugs, thus resistance 
of M.tuberculosis to INH occurs more frequently when compared to other drugs (111). As a 
result,  global increase in the incidence of INH resistant M.tuberculosis strains have been 
observed over the years, with estimates of 10% in new cases and 27 % in previously treated 
cases (23). In addition, INH resistance has been associated with high level mutations in the 
katG gene and four other genes (inhA, kasA, ndh and ahpC) of M.tuberculosis (27). However, 
only 70-80% of INH resistant clinical isolates are phenotypically resistant (87). The inability 
to genotypically detect INH resistance in these isolates could be due to the presence of 
mutations in other unidentified genes or mechanisms.  
This review will focus on the strategies adapted by M.tuberculosis to evade the toxic effect of 
INH by assessing not only (i) mechanical barrier but also mechanisms that are relevant to 
INH resistance such as (ii) target protection barrier and (iii) enzymatic barrier. A combination 
of these mechanisms might play a major role in the ability of M.tuberculosis to counteract 
INH toxicity. 
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2. MECHANICAL BARRIER   
Mechanical barrier is one of the protective strategies employed by M.tuberculosis against 
INH. This is done by modifying the membrane permeability through decrease of porins or in 
M.tuberculosis case by alteration of lipoglycans (51,93) which are large molecules consisting 
of a lipid and a polysaccharide joined by a covalent bond found in the cell wall of gram-
negative bacteria (4).   
2.1. M.tuberculosis cell wall 
M.tuberculosis has a very complex cell wall, composed of an insoluble matrix of cross-linked 
peptidoglycans linked to arabinogalactans (AG), esterified at the distal ends of mycolic acids  
(7,86). Additionally lipoarabinomannan (LAM) and mannosylated phosphatidyl inositol (PI) 
which are presented in the outer layer of the cell envelope are anchored in the cell membrane 
by lipidic position (11). An equally vital component of the mycobacterial cell wall is the 
mycolic acid, which constitutes up to 60% of the cell wall and is primarily accountable for 
the integrity and low permeability of the cell wall (7,17) which ensures that the tubercle 
bacillus is protected from the host‟s immune system and other toxic compounds (39). 
Consequently, mycolic acid synthesis has proven to be important for the pathogen‟s survival 
and growth (39). In addition, mycolic acids have a distinctive chemical nature and cell wall 
biosynthetic enzyme involved in their biosynthesis, formed targets for the design of anti-TB 
drugs such as (isoniazid (INH), isoxyl (ISO), thiolactomycin (TLM), ethambutol (EMB) and 
ethionamide (ETH)) (8,121) (Figure 1). 
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Figure 1: Representation of mycobacterial cell wall and location of the action site of anti-TB 
drugs targeting cell wall constituents 
 
 
2.1.1. Peptidoglycan 
Peptidoglycan is a polymer that consists of identical alternating chains of N-
acetylglucosamine (GlcNAc) and N-acetylmuramic acid (MurNAc), cross linked to 
arabinogalactan (AG) (30). Synthesis of the peptidoglycan monomers takes place in the 
cytosol by sequential addition of L-Ala, D-Glu, meso-diaminopimelic acid and dipeptide D-
Ala-D-Ala, catalyzed by MurA and MurC which is unique to mycobacteria (30,131). The 
monomers are then transported across the cytosolic membrane by a membrane carrier 
molecule, bactoprenol (9). The bactoprenol with the help of the transglycosidase enzyme 
Mycolic acid (INH, 
ETH, TLM, ISO) 
Arabinogalactan (EMB) 
Lipoarabinomannan 
(EMB) 
 
 
Peptidoglycan 
Cytoplasmic 
membrane 
Cell wall 
Legend to figure 1: INH = Isoniazid, ETH = Ethionamide, TLM = Thiolactomycin, ISO = Isoxyl, EMB = Ethambutol 
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insert the peptidoglycan monomers to existing peptidoglycan which enables the bacteria to 
grow (Figure 2). Peptidoglycan structure is orientated in such a way that the mycobacteria 
cell wall retains its structural integrity and thus protected from degration by enzymes or 
antibiotics (97). 
 
MurNAc GlcNAc
MurNAcGlcNAc
MurNAc GlcNAc
GlcNAc MurNAc
Cytoplasmic membrane
Cytoplasmic
Bactoprenol
Peptidoglycan monomers
Transglycosidase enzyme (TG)
GlcNAc MurNAc
TG
 
 
 
 
 
Legend to figure 2: GlcNAc = N-acetylglucosamine, MurNAc = N-acetylmuramic acid, TG = Transglycosidase enzyme 
Figure 2: Mycobacterial biosynthesis of peptidoglycan 
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2.1.2. Arabinogalactan  
Arabinogalactan (AG) is the second most dominant macromolecule in the mycobacterium 
cell wall, it is covalently linked to mycolic acids and peptidoglycan which then subsequently  
forms the mycolyl-arabinogalactan-peptidoglycan complex (mAGP) (30). The polymer is 
structurally unique in that is it composed of both D-arabinose (D-Araf) and D-galactose (D-
Galf) in a furanose configuration which is rarely found in nature (11,30). The galactan is 
linked via the linker region (α-L-Rhap-(1-3)-α-D-GlcNAc-P) (30) to the muramic acid 
residues of peptidoglycan, while the arabinan chains are attached to the galactan core via the 
C-5 of some 6-linked Galf units (30). The arabinan are further linked to the peptidoglycan via 
the diglycosylphosphoryl bridge (L-Rhap-(1-3)-D-GlcNAc-1-P) and mycolic acids are located 
in clusters of four on the terminal arabinofuranosyl units which are added by a set of unique 
arabinofuranosyltranferases (AraTs) (Figure 3) (106). Three of the AraTs which form part of 
the Emb protein (EmbA, EmbB and EmbC) have been shown to be present in both M.avium 
and M.tuberculosis (10,146), and the recently discovered proteins include AftA , AftB and 
AftC (1,123). The mAGP complex provides a linked network between the mycolic acid and 
the cytoplasmic membrane, thus making the mycobacterium cell wall difficult to permeate 
(30).  
 
 
 
13 
 
 
Figure 3: Mycobacterial biosynthesis of arabinogalactan 
Decaprenyl phosphate  (P-C50)
UDP-GLcNAc
UMP
GLcNAc-P-P-C50
dTDP-Rha
dTDP
Rha-GlcNAc-P-P-C50
UDP-Galf
UDP
Galf –Rha-GlcNAc-P-P-C50
UDP-Galf
UDP
Galf –Rha-GlcNAc-P-P-C50
AftA
Ara-Galf –Rha-GlcNAc-P-P-C50
embA,embB
AftC,aftB
DPA
DP
(Mycolyl) (Araf)-(Galf) –Rha-GlcNAc-P-Peptidoglycan
Peptidoglycan
D-Galactose
D-Arabinose
 
 
2.1.3. Lipoarabinomannan  
Lipoarabinomannan (LAM), phosphatidylinositol mannosides (PIMs) and lipomanna (LM) 
major lipoglycans found in the M.tuberculosis cell envelope (14,18). They are located at the 
exterior of the cell wall were they are attached to the plasma membrane by a phosphatidyl-
myo-inositol anchor (18,92). Additionally, M.tuberculosis LAM has short mannose 
containing oligosaccharide “caps” which allows it to bind to the mannose receptors on 
macrophages (92).  
Legend to figure 3: P-C50 = Decaprenyl phosphate, Rha = rhamnose, GlcNAc = N-acetylglucosamine, GalF = 
Galactofuran, AraF = Arabinofuran, DPA = Decaprenyl- 
1-monophosphoarabinose, UDP 
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LAM biosynthesis involves conversion of phosphatidylinositol (PI) to PIM via the 
mannosyltranferases (manT) catalyzed by PimA, PimB and PimC (47,66,68), further 
elongation of PIM leads to formation of the liner α1.6-linked mannan backbone of LM and 
LAM (147) (Figure 4). Although the function of LAM in the cell wall integrity is unclear, 
LAM displays pathology that is characteristic of TB, which include stimulation of 
macrophages to produce TNFα (18), nitric oxide and matrix metalloproteinases (18,24), 
inhibits activation of T-cell (24) and macrophage activation by interferon-γ (25).  LAM is 
thought to be involved in the synergy between the Human Immuno Deficiency Virus (HIV)-
TB , as it is capable of inducing transcriptional activation of HIV-1 (77).  
Figure 4: Mycobacterial synthesis of lipoarabinomannan (13) 
PI
PIM
Ac PIM
Ac PIM
GDP-Man
GDP
Ac-CoA
CoA
GDP-Man
GDP
2 X GDP-Man
2 X GDP
PimA
Rv2611c
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ManT
PimC
Ac PIM LM LAM
ManT
PPM PP DPA DP
PP
M
p
tA
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p
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2
1
8
1
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Legend to figure 4: PI = Phosphatidylinositol, PIM = PI mannoside, PPM = Polyprenylphosphomannose,  LM 
= lipomannan, LAM = Lipoarabinomannan, ManTs = Mannosyltransferases  
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2.1.4. Mycolic acids  
Mycolic acids are long-chain α-alkyl-β-hydroxy fatty acids (7). M.tuberculosis contains three 
families of mycolic acids: α-mycolic acids which constitute 70% of all the mycolic acids, 
methoxy and keto mycolic acid (7,143). Depending on the source, mycolic acids can vary in 
length of terminal, alkyl groups and number of methylene group (50). An example is the 
structural difference of α-mycolic acid from H37Rv and Canetti strains (115,143). Mycolic 
acid occur within the fluid matrix in the form of free trehalose dimycolate (TDM) and 
trehalose monomycolate (TMM) and both of these components are potent antigens and have 
been implicated in the pathogenesis of tuberculosis (43,57,58,75).  
 
Mycolic acids are primarily synthesised by the fatty acid synthase (FAS) enzymatic system, 
found in mycobacteria as FAS-I and FAS-II complexes (12,122). The FAS-I complex is 
capable of synthesising and generating short chain fatty acid. The FAS-II multienzymatic 
complex further elongates the short chain fatty acids generated by FAS-I (12,122). Mycolic 
acids formation involves four unique pathways: (i) formation of short-chain acyl CoA of 
between C24-C26 catalyzed by the FAS-I enzyme, (ii) synthesis of C58-acyl-ACP 
(meromycolate) from C16-acyl CoA by FAS-II system composed of multiple enzymatic 
reactions (iii) introduction of other functional groups to meromycolate by numerous 
cyclopropane synthases and (iv) final claisen condensation with C24-acyl CoA of FAS-I 
catalysed by the polyketide synthase Pks13 and various mycolyltransferase processes to  
produce α-mycolic acids, methoxy- and keto mycolic acids (44,45,105,122), followed by the 
transfer of mycolic acids to arabinogalactan (133) (Figure 5). 
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mycolic acid maturation
Cell membrane
Cell membrane
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Legend to figure 5:  FAS = fatty acid synthase, InhA = NADH-dependent enoyl-[acyl-carrier-protein] reductase, AcpM = 
Acyl carrier protein, Kas = β-ketoacyl- ACP synthase, Fas = Probable fatty acid synthase, plsB = Possible acyltransferase, Acc 
= Acetyl /propionyl  CoA carboxylase, Fad = Probable acyl-CoA dehydrogenise, Pks13 =  Polyketide synthase, FbpC = 
Trehalose dimycolyl tranferase, NADH = nicotinamide adenine dinucleotide  
 
 
 
 
 
 
 
 
Figure 5: Representation of Mycobacteria mycolic acid biosynthesis pathway (MAP) 
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2.2. Anti-TB drugs targeting M.tuberculosis cell wall 
The distinctive structural composition of the M.tuberculosis cell wall is the site of action of a 
number of powerful anti-TB drugs and to a certain extent is responsible for resistance of most 
of these drugs including INH (17,119) (Figure 1). EMB a first-line anti-TB drug which 
targets both the AG and LAM biosynthesis is used in combination with other anti-Tb drugs to 
prevent mono-drug resistance (132). EMB inhibits numerous AraT‟s, which are encoded by 
the embCAB operon (135,147). Ethambutol resistance in M.tuberculosis strains has been 
associated with mutations found in the embB, embA and embC genes, most of which are 
found at codon embB306 and most recently also at codon embB406 and embB497 (59,135).     
Thiolactomycin (TLM) is a unique thiolactone (37) that inhibits the FAS-II complex of many 
mycobacteria and as a consequence hinders synthesis of mycolic acid (125). TLM targets 
mycobacterial β-ketoacyl synthase III (fabH), which is an essential link between the FAS-I 
and FAS-II complexes (124). Another compound that was used as an anti-TB drug during the 
1960s is a derivative from thiourea, Isoxy (ISO) (125). It has been reported that ISO inhibits 
both the mycolic acid and free fatty acids synthesis of all slow and fast growing 
Mycobacterium species (124), especially that of Mycobacterium bovis BCG (67). In addition, 
it was later demonstrated that ISO also inhibits oleic acid biosynthesis by blocking the 
stearoyl co-enzyme A (CoA) and desaturase DesA3 involved in lipid metabolism in the 
mycobacterial cell envelope (103). 
Ethionamide (ETH) is a structural analogue of INH (118). Both these drugs are prodrugs and 
require intracellular activation to acquire bacteriotoxicity (3). Monooxygenase encoded by 
the EthA gene activates ETH (38). Subsequent to activation ETH inhibit mycolic synthesis by 
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targeting the enoyl acyl carrier protein (InhA) encoded by the InhA gene (3). Furthermore, 
isolates resistant to ETH have low level INH resistance which results from higher frequency 
of mutation found in the katG gene when compared to those found in InhA gene (142,150). 
 
2.3. Multidrug efflux pumps 
Intracellular concentration of drug mycobacterial cell is generally due to a balance between 
influx which is provided by the bacterial unique lipid-rich cell wall and efflux by active 
efflux pumps (41,93,140). Multidrug efflux pumps appears to be one of the major mechanism 
of resistance in wide variety of bacteria and has been shown to aid M.tuberculosis with 
intrinsic resistance to various anti-TB drugs (41,93). 
 
Drug transporters can be divided in two groups: those that use an ion gradient such as sodium 
or proton ions across the membrane and extrude drugs against an electrochemical gradient 
(31), included in this group are major facilitator superfamily (MFS), multidrug and toxic 
compound extrusion (MATE), resistance-nodulation-cell division (RND) and small multidrug 
resistance (SMR) transporters. The second class uses free energy in a form of ATP to pump 
drugs out of the cell and mainly include the ATP-banding cassette (ABC) families (69,79). 
 
Drug efflux-related mechanisms in INH resistance have been described in a number of 
mycobacteria (28,73,74,100). For instance the M.tuberculosis mycobacterial membrane 
protein (MmpL7) catalyzes the export of phthiocerol dimycocerosate (PDIM) and 
overexpression of the MmpL7 gene in M.smegmatis has been shown to present high-level 
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INH resistance, whereas a decrease in resistance level was observed in the presence of efflux 
inhibitors (100). This result was  explained by the observed association of MmpL7 in the 
energy-dependent efflux of INH (100). The ini region has a total of four genes, three of which 
are organized as an operon (iniA,iniB and iniC) with the Rv0340 gene located of upstream the 
iniBAC operon (2). Analysis of iniA gene in M.tuberculosis through knockout studies have 
proven that the iniA gene is essential for the MDR-pump like mechanism that confers 
tolerance to both INH and ETH (29). Several MFS efflux pumps have been shown to be 
regulated in M.tuberculosis through gene expression studies after INH induction, these 
include (efpA, pstB, Rv1258c and Rv1410c) and ABC transporters (Rv1819c and Rv2136c) 
(42,61,108,141,145) (Table 1). 
  
Collectively these results suggest that efflux related mechanisms may influence the 
intracellular concentration of activated INH in the mycobacterium cell and therefore might be 
involved in M.tuberculosis INH resistant isolates which do not have genomic mutations 
associated with the drug.  
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Table 1: Efflux pump genes and transporters regulated by INH in M.tuberculosis 
Efflux 
gene 
Transporter Function Protein product reference 
MmpL7 RND Export of antibiotic transmembrane transport protein (35,100) 
pstB ABC Active import of inorganic phosphate 
and export of drugs 
Phosphate-transport ATP-binding protein (117) 
iniA membrane 
protein 
Drug transport INH inducible protein iniA (2,29) 
iniB membrane 
protein 
Drug transport INH inducible protein iniB (2) 
iniC membrane 
protein 
Transcriptional mechanism INH inducible protein iniC (2) 
efpA MFS Export of drugs Integral membrane efflux protein (76) 
Rv1747 ABC Transport of drug across the 
membrane. 
conserved transmembrane ATP-binding protein  (62,85) 
Rv1410c MFS Export of drugs Aminoglycosides/tetracycline-transport integral 
membrane protein 
(110) 
Rv1258c MFS Export of drugs Conserved membrane protein (31) 
Rv1819c ABC Export of drugs probable drug-transport transmembrane ATP-
binding protein  
(16) 
Rv2136c ABC Unknown Possible conserved transmembrane protein (16) 
Rv2459 MFS Transport of drug across the 
membrane. 
Probable conserved integral membrane transport 
protein 
(49) 
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3. TARGET PROTECTION BARRIER 
3.1 Genomic alteration 
The mycolic acid pathway (MAP) involves numerous reactions of multiple genes, yet only 
few and essential genes have undergone alteration due to INH treatment (133,134). It seems 
that the tubercle bacilli has evolve a survival strategy to protect itself from INH by acquiring 
mutations at selected multiple genomic positions that strongly decrease the affinity of the 
drug to the target site. 
Mycobacterium catalase peroxidase enzyme, encoded by katG gene serves as both a catalase 
to protect M.tuberculosis from reactive oxygen species produced by the microphage and also 
functions as a peroxidase, to activate INH into a isonicotinonyl acyl radical (144). Mutations 
in the peroxidase are a major mechanism of INH resistance in M.tuberculosis clinical isolates 
(148), approximately 130 mutations with minimum inhibitory concentration (MIC) ranging 
from 0.2 and 256µg/ml associated with INH resistance (54,107,149). Mutations at codon 
Ser315Thr are the most common found in 50-90% of INH resistance isolates and associated 
with high level INH resistance (137). Complete deletion of katG gene is rare (15,127) and if 
it ever occurs it was only found in less than 5% of the INH resistance isolates (54). Mutations 
in katG results in reduced peroxidise activity resulting in the inability to activate INH 
(52,109), this in turn causes poor formation of the INH-NAD adduct preventing it from 
binding to InhA (26).  
A direct link between the synthesis of mycolic acids and INH was first described in 1994 by 
the identification of InhA as a target for INH (128). The inhA gene was shown to have a non-
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synonymous mutation at codon Ser94Ala located in the binding pocket of NADH which 
reduces binding of the activated INH radical to NAD (3) and consequently disturbs binding 
of INH-NAD adduct to InhA (8,33). Other mutations located in the binding pocket of inhA 
gene include (lle16Thr, lle21Thr, lle21Val, lle47Thr, Val78Ala, lle95Pro and lle194Thr)  
(120,137). However, INH resistance in M.tuberculosis clinical isolates have been commonly 
associated with inhA promoter mutations which are present at positions -8(T-G/A), -15(C-T), 
-16(A-G), -17(G-T) and -24(G-T) of which -15(C-T) is the most prominent (72,120). The 
consequence of these promoter mutations is overexpression of inhA gene, which leads to   
low level INH resistance (70).   
Another genomic alteration that confers resistance to INH is mutations found in ndh gene 
(22,109). This was first postulated in 1998 in the INH and ETH resistance isolates of 
M.smegmatis where reduced activity of NADH dehydrogenase due to mutations resulted in  
coresistance of INH and ETH (83). The ndh gene encodes type II NADH dehydrogenase 
(Ndh) found in the M.tuberculosis genome (83). To date two distinct mutations at codon 
T110A and R268H have been identified in the ndh gene of INH resistance M.tuberculosis 
clinical isolates (71,83) and mutations in this gene diminishes Ndh activity causing 
accumulations of nicotinamide adenine dinucleotide NAD(H) and reduction of NAD+ (71). 
This defect increases NADH intracellular level which competitively inhibit the binding of 
INH-NAD adduct to InhA and ultimately leads to co-resistance of INH and ETH (139). 
Alkyl hydroperoxide reductase enzyme (AhpC) is encoded by the ahpC gene, a member of 
peroxiredoxins (48). The enzyme  protects  M.tuberculosis from reactive oxygen species and 
is vital for oxidative stress response (39,48). Regulation of this protein takes place at the 
bacterial oxyR gene in most mycobacteria and appears to be linked to the altered expression 
of the ahpC gene (34,96). Mutations in oxyR-ahpC locus increase the expression of AhpC in 
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katG deficient INH resistant strains (130,141,145) which has been observed as a 
compensatory mechanism for the loss of catalase peroxidase in the strain (80). Therefore 
several aspects of oxidative stress response, including regulatory factors have been associated 
with inherent susceptibility and acquired resistance to INH (20,32).  
kasA gene which encodes ketoacyl acyl carrier protein synthase (kas) forms part of a five 
genes (kasA, kasB, accd6, acpM and fabD) operon which is vital for extension of mycolate 
from FAS-I during the synthesis of mycolic acid (129), although the role of this protein in 
INH resistant is still unclear, several mutations have been reported in the gene (104,129). The 
MAP is one of the important pathways involved in the survival of mycobacteria, multiple 
genomic alterations induced by INH treatment in this pathway might be a survival 
mechanism that the bacterium has evolved to shield itself against the toxicity of the drug 
3.2.  Mycothiol deficient 
Mycothiol (MSH) is a major thiol in mycobacteria and it is composed of  1-O-(2-amino-2-
deoxy-α-D-glucopyranosyl)-D-myo-isotol (116). It plays crucial role in detoxification of a 
variety of thiol-reactive agents (116). Biosynthesis of MSH in M.tuberculosis proceeds 
through a four-step pathway which involve the following seven genes: (i) glycosyltransferase 
mshA (91), (ii)  deacetylase mshB (89), (iii)  ligase  mshC (116), (iv)  mycothiol synthase  
mshD (65), (v) NAD/MSH-dependent formaldehyde dehydrogenase mscR (84), (vi)  
mycothione reductase mtr  and (vii) mycothiol S-conjugate amidase mca (88) (figure 5). 
A study conducted in 2003 has shown that M.tuberculosis  mutants lacking mshB activity 
showed a twofold increase in INH resistance and M.smegmatis mutants which had transposes 
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in either mshA, mshC or mshD were also found to be resistance to INH (19). On the contrary, 
M.smegmatis mutants lacking MshB activity were found to be sensitive to INH (112). More 
recently mycothiol have been shown to play a role in the activation of ETH by the ethA-
encoded mono-oxygenase and are therefore essential for ETH susceptibility in M.tuberculosis 
(136). Although further studies are needed to elucidate the initial step of MSH biosynthesis it 
might be that MSH-dependent detoxification in combination with other mechanism facilitate 
the removal of INH from the bacterial cell. 
 
Figure 3: (I) Mycothiol biosynthesis pathway (90) and (II) MSH-Mediated Detoxification 
(88) 
  
 
 
 
 
 
 
 
Deacetylase Ligase Acetyltransferase 
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Legend of figure 3: Ac = Acetyl, CoA = coenzyme A, GlcN = glucosamine, MCA =   mycothiol-S-conjugate amidase, 
MSH = Mycothiol, AcCys = mercarpturic acid  
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4. ENZYMATIC BARRIER  
 
Antibiotic modification by M.tuberculosis may be an additional way that the bacteria acquire 
resistance to INH, in this case the tubercle bacillus employs N-acetyltranferase to modify the 
drug. 
4.1. Over production of arylamine N-acetyltranferase 
Arylamine N-acetyltranferase (NAT) exists in humans as two polymorphic isoforms (NAT1 
and NAT2) (53). The NAT2, a hepatic phase II drug-metabolizing enzyme is responsible for 
the acetylation of INH in the liver via the acetyl coenzyme A (acetyl-CoA) (126). After 
acetylation, acetyl-iso-isoniazid (Ac-INH) is formed and it is further hydrolyzed into iso-
nicotinic and mono-acetyl hydrazine (MAH) (40,99). Single-nucleotide polymorphisms 
(SNPs) of NAT2 determines pharmacogenetic variations in humans (81), and can be used to 
distinguish between slow, intermediate and fast acetylator phenotypes for INH (53). 
Subsequent to INH treatment the NAT2 slow acetylators excrete large amounts of INH 
relative to NAT2 fast acetylators (99). The common cause of NAT2 slow phenotype has been 
explained by NAT2 decreased expression which bears amino acid substitution at codon 
I114T, resulting from the T to C transition found in NAT2*5 alleles (94). 
A study done in 2001 showed that the nat gene encodes NAT in both M.tuberculosis and 
M.smegmatis, The investigators also reported that overexpression of M.tuberculosis nat gene 
in M.smegmatis resistant bacillus increased resistance to INH threefold (102). In addition, 
deletion of nat in the bacillus illustrated increased sensitivity to INH (101). Inactivation of  
INH by the nat gene in M.tuberculosis, results in the acetylation of the nitrogen group of INH 
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and doing so it inhibits INH activation by catalase peroxidase enzyme, rendering the drug 
therapeutically inactive (101,102). These results confirm that reduced activity of NAT shields 
M.tuberculosis from drug as a result of lower activity or mutation in genes encoding N-
acetyltranferase. 
 
5. CONCLUDING REMARKS  
Resistance of M.tuberculosis to INH is mainly due to various genomic mutations in the drug 
main target (MAP). However, there are M.tuberculosis clinical isolates resistant to INH that 
does not present these mutations, which clearly indicates that M.tuberculosis utilizes 
additional resistant mechanism for INH. Intrinsic resistant is one of the major resistant 
mechanisms that a broad variety of bacteria employ and it mainly involves the balance 
between influx provided by the lipid rich membrane and efflux presented by the efflux 
pumps. INH enters the cell by passive diffusion which allows the drug to escape the cell wall 
barrier. Alteration in the gene responsible for the activation of the drug insures that the bacilli 
is protected from the toxicity of the drug which can be viewed as a second line of protection 
after penetration of the bacterial complex lipid-thick cell wall. In addition, the bacterium can 
regulate the intracellular regulation of INH by activating the efflux pumps thereby causing 
the extrusion of the activated drug from the bacterium. In doing so the bacteria survives and 
go on further to acquire resistance. Therefore, M.tuberculosis protection against INH might 
involve a combination of mechanical barrier (cell wall and efflux pumps), target protection 
barrier (genomic alteration) and enzymatic barrier (antibiotic modification). 
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Further understanding on how these mechanisms interlink to serve as a protective mechanism 
to INH toxicity in M.tuberculosis may help to improve existing anti-TB drugs and provide a 
novel approach to development of new anti-TB drugs. 
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Chapter 3 
 
MATERIALS AND METHODS 
 
3.1 Selection of candidate genes by literature searches 
Candidate genes were selected from reported literature and included genes involved in the 
mycolic acid synthesis pathway (targeted by INH) and those involved in drug transport 
(1,3,4,9,12). 
 
3.2 Selection of M.tuberculosis clinical strains 
  
M.tuberculosis clinical isolates from the Beijing cluster 208 INH susceptible (K636) and INH 
mono-resistant strains (R55) were selected from a longitudinal reference database with well 
characterized isolates which is maintained at the University of Stellenbosch. Phenotypic 
characterization of these isolates included drug susceptibility testing in BACTEC 12B 
medium (Becton Dickinson, USA) at the critical concentration of 0.1µg/ml INH. Subsequent 
minimum inhibitory concentration (MIC) determination for the susceptible (K636) and the 
resistant (R55) isolates showed MIC‟s of 0.1 µg/ml and 4µg/ml INH, respectively. In 
addition, these isolates were genotypically characterized by spoliogotyping (5), IS6110 DNA 
fingerprinting (11) using internationally standardized methods (Table 4.1).  
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3.2.1 Single colonies isolation 
To select single colony forming units, undiluted glycerol stocks of the selected INH 
susceptible (K636) and INH mono-resistant (R55) strains were inoculated into Middlebrook 
7H10 agar (supplemented with 0.2 % (v/v) glycerol, oleic acid-dextrose-catalase 10% 
OADC) containing (0.01, 0.1 and 4 µg/ml) concentration of INH. Control agar plates did not 
contain any INH. The plates were incubated at 37°C for 21 days to allow for colony 
formation. Single colonies were picked and subsequently cultured in 20 ml of enriched 7H9 
Middlebrook medium (supplemented with 0.2 % (v/v) glycerol, 0.1 % Tween 80 and 10% 
OADC) and incubated at 37 °C without shaking for 14 days. At this stage 10ml of the culture 
was stored in 1 ml aliquots at -80 °C until required. 
 
3.2.2 DNA isolation 
Crude DNA was isolated by boiling an 1ml aliquot of the cultured single colony inoculum of 
each isolate in a 1.5 ml eppendorf tube (Merck, New Jersey, USA) for 30 minutes at 80°C. 
The crude DNA templates were then stored at -20°C prior to DNA sequencing. 
 
3.2.3 Primer design and mutation screening 
Primers were designed for amplification using Primer software 3 version 0.2 (Whitehead 
Scientific) and sequencing of known INH resistance causing gene mutations (katG, inhA, 
kasA, ndh, ahpC) (Table3.1). Gene sequences were searched on 
(http://genolist.pasteur.fr/TubercuList).  
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3.2.4 PCR amplification 
 DNA amplifications were done in 25 µl reaction volumes. The PCR master-mix consisted of 
5µl 5X Q-solution, 2.5µl 10X reaction buffer, 2 µl MgCl2 (25mM), 4 µl deoxyribonucleotide 
triphosphates (dNTPs) (0.2mM of each dNTP), 0.5 µl Forward primer (50pM), 0.5 µl 
Reverse primer (50pM), 0.125 µl Hotstar Taq polymerase (5 units/µ), 1.25 µl of the crude 
DNA template, and 7.85 dH2O to make up a final volume of 25 µl. The reaction mixtures 
were heated in the thermal cycler (GeneAmp PCR System 2400, Applied Biosystems, Foster 
City, CA, USA). Successful amplification of the DNA fragment was assessed by 
visualization on a 1.5% agarose gel (Sigma-Aldrich, St. Louis, USA) stained with ethidium 
bromide.  
 
3.2.5 Sequencing 
DNA sequencing was done on ABI3730xl DNA analyzer at the Central Analytic Facility of 
Stellenbosch University. Sequences were then compared with the whole genome sequence of 
M.tuberculosis H37Rv reference (http://genolist.pasteur.fr/TubercuList) to determine if 
mutations are present in the candidate genes from different M. tuberculosis isolates. 
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Table 3.1: PCR primers and conditions used to amplify genes associated with INH resistance 
         Region                      Forward / Reverse primers                              Tm (°C)             Amplification fragment (bp)              Reference 
 
                5‟ CAGAAACCACCACCGGAGCC „3                                     59                                               945           (9) 
                5‟ GCTGGTGATCGCGTCCTTAC‟3              
                5‟TGGCCGCGGCGGTCGACATT‟3                                         64                                                804         (9) 
                5‟TCGGGGTCGTTGACCTCCCA‟3                                          
                5‟CCGACGATGCTGGCCACTGA‟3                                         62                                    997                            (9) 
                5‟GACCTCGACAAGCGCCCGCA‟3                                         
 
                5‟CGGGCAACAAGCTCGACGGG‟3                                     64                                                       169         (9) 
                5‟GGGTTCATGATCGGCAGGAG‟3                                         
 
                 5‟CGCAGCCAGGGCCTCGCTG‟3                                             60                                                      246        (9) 
                5‟CTCCGGTAACCAGGACTGA‟3 
 
               5‟GCTGATTGTCCGAGAGCATCG‟3                                        60                                                      701        (10) 
               5‟GGTCGCGTAGGCAGTGCCCC‟3                                           
 
               5‟CCGATGAGAGCGGTGAGCTG‟3                                      66                                  236                 (10) 
               5‟ACCACTGCTTTGCCGCCACC‟3   
 
 
               5‟ATCACCACCGCCGCTGAAGC‟3                                          65                                                     1135        (10) 
               5‟GTTCGGGTACCCGGGAATG‟3                                             
               5‟CATTCCCGGGTACCCGAAC‟3                                             65                                                       535        (10) 
               5‟GTCGACCGTTTTGGCGTTGG‟3                                             
 
               5‟GTTCAGGCGAGGCTTGAG‟3                                               50                                  1293        (10) 
               5‟GCGATGTCGTGCTTCAGTAA‟3                                            
 
 
 
 
katG 
InhA gene 
Inh A  promoter 
 ahpC  promoter
ahpC intergenic
ndh 
kasA 
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3.3 M.tuberculosis culture conditions and drug treatment 
M.tuberculosis Beijing cluster 208 fully susceptible (K636) and INH mono-resistance (R55) 
strains were grown on Lowenstein-Jensen (LJ) slants with continuous aeration for 
approximately three weeks. Colonies were scraped from the LJ slants and inoculated into 5 
ml 7H9 Middlebrook medium (supplemented with 0.2 % (v/v) glycerol, 0.1 % Tween 80 and 
10% ADC) and incubated at 37 °C without shaking, until an OD600 of 0.6-0.8 was reached. 
Thereafter these starter cultures were inspected for contamination by Ziel-Neelsen gram 
staining and culture on blood agar plates. At this stage 1ml aliquots were stored at -80 °C 
after which a sub-starter culture was setup by inoculating 800 µl freezer stock into 80 ml 7H9 
media and incubated at 37°C without shaking, until an OD600 of 0.6-0.8 was reached.  
Two biological replicate experiments were performed (to assess biological measurements for 
two independent experiments done on different days) and 2 technical replica experiments (to 
measure each biological sample on the same day) for each strain. The 80 ml liquid culture 
was divided into 2 x 40 ml cultures; INH (0.1 µg/ml) was added to one  40ml  culture, while 
the remaining 40 ml was untreated and served as the control. Both cultures were subsequently 
incubated at 37°C for 24 hours. 
 
3.4 RNA isolation and purification 
Subsequent to the 24 hours incubation, 200ml of Guanidinium thiocyanate (5M) (GITC) 
(Sigma-Aldrich, St. Louis, USA) solution (5M GITC, 0.5% sodium N- lauroyl sarcosine, 
0.1M β-mercaptoethanol, 12.5ml of 1M sodium citrate pH7.0 and 1% Tween 80) made up to 
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500ml with RNase free water was immediately added to each 40 ml culture. Bacterial cells 
were harvested by centrifugation (3000rpm for 15 min, 20°C) and the supernatant was 
discarded. The pellet was resuspended in 1 ml TRIzol (Sigma-Aldrich, St. Louis, USA). The 
TRIzol suspension was transferred to a 2 ml lysing matrix tube containing silica beads 
(IEPSA) and ribolyzed for 45 seconds at 6 Watts for 3 cycles and cooled on ice for 1 minute 
between pulses. The samples were centrifuged at 12000 rpm for 10 min and the TRIzol 
solution above the bed of the beads was transferred to a 2 ml phase lock gel tube (Eppendorf, 
Hamburg 22331, Germany) containing 300µl chloroform (Sigma-Aldrich, St. Louis, USA),  
and vigorously mixed. Samples were incubated at room temperature for 5 min to allow phase 
separation. The aqueous layer was recovered by centrifugation at 12000 rpm for 10 min and 
the top aqueous layer was transferred into a new 1.5 ml eppendorf tube. The RNA was 
precipitated with the addition of an equal volume of isopropanol (Merck, Darmstadt, 
Germany). This was followed by incubation at room temperature for 5 3.7min and then 
incubation at 4°C overnight. 
 
Crude total RNA was collected by centrifugation at 12000 x g, 30 min at 4°C and the pellet 
was washed with 70% ethanol (Merck, Darmstadt, Germany), air-dried and re-dissolved to 
final concentration 70 µl RNase-free water. Possible DNA contamination was removed by 
digesting a 10µl aliquot of total RNA with 1 unit of RQ1 DNase (Promega) at 37°C for 30 
min. To inactivate the digestion reaction DNase treated RNA was diluted to a final volume of 
200 µl with RNase-free water and equal volume of phenol:chloroform (4:1) (Merck, 
Darmstadt, Germany) was added to the RNA, gently mixed and set on ice for 10min. The top 
layer was collected by centrifugation at 12000 rpm for 10 min at room temperature and 
transferred to a new tube. Subsequent addition of 0.1 volumes of 3M Sodium acetate pH 5.2 
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and 2.5 volume of 100% ethanol, followed by incubation at 4°C overnight. Purified RNA was 
pelleted by centrifugation (30 min, 12000 x g, 4°C), washed with 70% ethanol and collected 
by centrifugation at 12000 x g, for 10 min at 4°C. Ethanol was removed and the purified 
RNA was air-dried and re-dissolved in 20µl RNAse free-water and stored at -80°C until 
further use. The total RNA quality and quantity was assessed by various methods shown in 
figure 4.1. 
 
3.5 cDNA synthesis and primer design for selected candidate genes 
Purified RNA was used to synthesize cDNA according to manufacturer‟s instructions 
Quantitect Reverse Transcriptase kit (Southern Cross biotechnology). One microgram RNA 
was mixed with 2 µl genomic DNA Whipeout Buffer and RNase-free water to a final volume 
of 14 µl and incubated for 2 minutes at 42°C. After incubation Quantiscript Reverse 
Transcriptase, Quantiscript RT buffer, and RT Primer Mix was added to the RNA mix and 
incubated for 15 minutes at 42°C. After incubation the mix was incubated for 3 minutes at 
95ºC to inactivate the Quantiscript Reverse Transcriptase. Gene sequences for candidate 
genes were searched on (http://genolist.pasteur.fr/TubercuList) and subsequent primers were 
designed using Primer software 3 version 0.2 (Whitehead Scientific) (Table 3.2).  
 
3.6 Quantitative Real-Time PCR (QRT-PCR) 
A volume of 1µl of each primer pair (10µM) (Table 4.3), 2µl LightCycler FastStart DNA 
masterplus SYBR green Mix (Roche Diagnostics, Indianapolis, USA 0001), 2µl of diluted 
cDNA (1:10) and RNase free water was added to the master mix in a 20 µl reaction. QRT-
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PCR was performed using LightCycler 2.0 system (Roche Diagnostics). A four step PCR 
parameter protocol was used: denaturation program (95°C for 10 min), amplification and 
quantification program repeated for 45 cycles (95°C for 10 s, 59°C for 15 s, 72°C for 6 s), 
melting curve program (95°C for 0 s, 60°C for 15 s, 95 °C with a heating rate of 0.1°C /s ) 
and cooling  program of 40°C or 30s. Each QRT-PCR experiment was done on duplicate 
biological samples that were each assayed in duplicate. 
 
3.7 Data analysis  
The gene expression of target genes was determined by using the delta-delta Ct calculation  
in which the relative abundance of mRNA of the target gene was normalised relative to the 
level of reference RNA transcript (16srRNA and Ftsz) (6,7). Data analyses were done 
according to the delta-delta Ct equation R=2-(∆CT sample -∆CT control).   Only experiments with a 
standard deviation of <0.5 were included for analysis by Relative Expression Software Tool -
384 (REST-384©) which  determines whether there is a significant difference between two 
groups of samples, taking into account issues of reaction efficiency and reference genes 
normalization. The software identifies significant fold changes and assigns significance with 
a significance level of 5% (8). In this study increase or decrease of at least fivefold in gene 
expression was considered significant. 
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Table 3.2: Primers used for QRT-PCR analysis 
Gene Forward/Reverse primers Size (bp) Tm(oC) Reference 
katG 5‟ GAG CCC GAT GAG GTC TAT TG 3‟ 
5‟ ACG TAG ATC AGC CCC ATC TG 3‟  
120 60 (9) 
furA 5‟ AAC CAC CAT CAC ATC GTC TG 3‟ 
5‟ GTC ACC CAG GAA GCC GTT AT 3‟ 
115 60 Current study 
ahpC 5‟ TCA GCA AGC TCA ATG ACG AG 3‟ 
5‟ ATC GGG AAG GGT AAC GTT TT 3‟ 
120 60 (9) 
ndh 5‟ CTT ATT TCG GCA ACG ACC AT 3‟ 
5‟ CGA CAA CGG TGA ATG TCA GT 3‟ 
100 60 Current study 
dfrA 5‟ GCT GAG GTT GTC GGT TCA CT 3‟ 
5‟ CGA CCT CGG TAA CCT CAC AT 3‟ 
120 60 Current study 
InhA 5‟ ATC CAC ATC TCG GCG TAT TC 3‟ 
5‟ ACC GTC ATC CAG TTG TAG GC 3‟ 
100 60 (9) 
acpM 5‟ AGG ACA AGT ACG GCG TCA AG 3‟ 
5‟ GGG GTT CTC CGA CTC AAT CCT 3‟ 
120 60 (9) 
kasA 5‟ CCG  ACC CTG AAC TAC GAG AC 3‟ 
5‟ AAC CCG AAC GAG TTG TTG AC 3‟ 
100 60 (9) 
fas 5‟ CGA TGC AGA CGA TGT ACC AG 3‟ 
5‟ CCG ACG TAG GAC TGA ACC AC 3‟ 
120 60 Current study 
plsB 5‟ GCT GAA GCC AAT TTT GTG GT 3‟ 
5‟ GTC ACC GTC GGC ATA GAA GT 3‟ 
100 60 Current study 
fabD 5‟ CAA ACC GAG GGA ATG TTG TC 3‟ 
5‟ CGG TGT CGG TGA TCT CCT C 3‟ 
100 60 Current study 
fadE 5‟ AGC CAG CGA CAA CGA CTA TT 3‟ 
5‟ TTC ACA TAC GGG ACG ACG TA 3‟ 
120 60 (9) 
accD6 5‟ TCG AAG ACC AGA GTC CCA TC 3‟ 
5‟ AGA TCT GCG GGA TGT AGC C 3' 
120 60 (9) 
Pks13 5‟ CAC GAC GTC GAA TAC TGG AA 3‟ 
5‟ AGC TCC AGG AAG GTG GTG T 3‟ 
120 60 Current study 
fbpC 5‟ ATA TCT GCA GGT GCC ATC C 3‟ 
5‟ ATG TCC CAG CCG TTG TAG TC 3‟ 
120 60 (9) 
efpA 5‟ TAG GTT TCA TCC CGT TCG TC 3‟ 
5‟ CAC GGT GCA TGA AAA ATG AG 3‟ 
115 60 (2) 
iniA 5‟ AAG ATG ATC CAG CGT CTG CT 3‟ 
5‟TTG ACC TGG CTC AGG ATA CC 3‟ 
173 60 (2) 
iniB 5‟ GCT AGC CAG ATC GGT GTC TC 3‟ 
5‟ CGA CAG ATG AGG CAT AGC AG 3‟ 
171 60 (2) 
Mmpl7 5‟ TGA AAT ACG GAA GCC TGG TC 3‟ 
5‟ GAG GTA AGA GGC CAG CAC AC 3‟ 
197 60 (2) 
pstB 5‟ GTT CCC GAT GTC AAT CAT GG 3‟ 
5‟ ACC ACC AGA GAG TCG AAA CG 3‟ 
166 60 (2) 
Rv1258c 5` GGT ATG CCG TGT TGG CTA TC 3` 
5` CCG CGT CTG TAT CAC GTA GTT 3` 
188 60 (2) 
Rv1747 5‟ TCT GGA GCT GTT CGT TGA TG 3‟ 
5‟ ACC CAG GAC ATC TGG TCA AG 3‟ 
192 60 (2) 
emrB 5‟ TTC GAC TAC ATG GGC CTC TT 3‟ 
5‟ TAT GAG CGG ATG TTC TGT GC 3‟ 
183 60 (2) 
Rv1819c 5'  CCG TCG TAG ATG GAA AAC AGG TG  3' 
5'  CGT CTC CTC ACA AAC AGA AAT CCT  3' 
 
115 60 Current study 
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                                                      Chapter 4 
RESULTS 
Table 4.1, illustrates genotypic and phenotypic characteristics of the two Mycobacterium 
tuberculosis Beijing clinical isolates used in this study.  
 
Table 4.1:  Genotypic and Phenotypic characteristic of selected strains 
Isolates Beijing 
cluster 
Spoligotype pattern IS6110 RFLP MIC 
(µg/ml) 
Phenotypic 
resistance profile 
Genotypic resistance 
profile 
K636 208  
IS6110 RFLP
 0.1 INH susceptible No mutations 
R55 208  
IS6110 RFLP
 4 INH-mono resistant No mutations 
 
 
4.1 Assessment of RNA integrity and quantity  
Figure 4.1, shows a representative of three quality controls measures: The integrity and 
quantity of RNA was verified by Experion software version 2.01 where the 16S and 23S 
rRNA appeared as sharp bends on a virtual gel (Figure 4A and 4B). The quantity and purity 
of the RNA was assessed spectrometrically by the nanodrop (Inqaba Technologies) at 
A260/A280 ratio of between 1.8 and 2.1 (Figure 4C), only extracts with absorbance (A260/A280) 
of between 1.8 and 2.1 were used in subsequent experiment. In addition, the extracted total 
RNA was also examined for possible DNA contamination on a non-denaturing 1% agarose 
gels (Figure 4D).  
Legend to table 4.1: MIC = Minimum inhibitory concentration, INH = Isoniazid 
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4.2 Literature search for candidate genes 
Twenty four candidate genes were selected from the literature. The selection criteria were as 
follows:  Fifteen of the candidate genes formed part of the mycolic acid pathway (MAP), the 
main target of INH and 9 drug transport genes shown previously to be induced by INH 
exposure (Table 4.2).  
 
 
 A  
C 
Legend to figure 4.1: (A) virtual gel profile from Experion software indicating the ladder peak, and 16S and 23S 
ribosomal peaks that is indicative of prokaryotic RNA profile, (B) Experion virtual gel profile showing the 
ladder and RNA bands, (C) RNA absorbance measurement from the NanoDrop indicating the concentration 
(ng/µl), 260/280 and 230/280 readings, (D) gel image from 1% agarose gel showing 23S, 16S and t RNA bands 
D 
23S rRNA 
  16S rRNA 
      t-RNA 
 B 
Figure 4.1: Representative quantification of RNA on different systems 
Ladder 
16S ribosomal peak 
23S ribosomal peak 
Ladder 
      t-RNA 
23S rRNA 
16S rRNA 
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Table 4.2: Selected candidate genes induced by INH based on literature searches. 
 
Genes Function Product Reference 
Mycolic acid pathway genes 
katG Catalase-peroxidase activity Catalase-peroxidase-peroxynitritase   (20,45) 
 
furA Global negative controlling element Ferric uptake regulation protein  (25,30,44) 
ahpC Oxidative stress response Alkyl hydroperoxide reductase C protein  (16) 
ndh Electron transfer Probable NADH dehydrogenase  (22,38) 
dfrA Intermediary metabolism Dihydrofolate reductase  (2,41) 
InhA Mycolic acid biosynthesis NADH-dependent enoyl-[acyl-carrier-
protein] reductase  
(36,37) 
acpM Fatty acid biosynthesis and 
meromycolate extension. 
Meromycolate extension acyl carrier protein  (21,33) 
kasA Fatty acid biosynthesis and 
meromycolate extension. 
3-oxoacyl-[acyl-carrier protein] synthase  (4,7) 
fas Lipid metabolism Probable fatty acid synthase  (34) 
plsB Lipid metabolism Possible acyltransferase   
fabD Lipid metabolism Possible malonyl coA-acyl carrier protein 
transacylase  
(18) 
fadE Mycolic acid synthesis Probable acyl-coA dehydrogenase (15,29) 
accd6 Fatty acid biosynthesis Acetyl/propionyl-coA carboxylase (14,29) 
Pks13 Synthesis of a polyketide molecule Probable polyketide beta-ketoacyl synthase (14) 
fbpC Lipid metabolism Secreted antigen 85  (39) 
Drug transport (Efflux pump) genes 
efpA Export of drugs Possible integral membrane efflux protein (9,12) 
iniA Drug transport INH inducible protein  (8) 
iniB Drug transport INH inducible protein  (1) 
Mmpl7 Export of antibiotic Transmembrane transport protein (11,27,28) 
pstB Active import of inorganic phosphate 
and export of drugs 
Phosphate-transport ATP-binding protein (32) 
Rv1258c Export of drugs Conserved membrane protein (10) 
Rv1747 Transport of drug across the membrane. conserved transmembrane ATP-binding 
protein 
(26) 
emrB Export of drugs Possible multidrug resistance integral 
membrane efflux protein 
(23) 
Rv1819c Export of drugs Probable drug-transport transmembrane 
ATP-binding protein 
(5) 
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4.3 Gene expression analysis in response to INH 
QRT-PCR analysis was done to determine the expression levels of the genes listed in table 
4.2 following exposure to 0.1 µg/ml INH for 24hrs in an INH susceptible (K636) and INH 
mono-resistant (R55) M.tuberculosis strain with identical Beijing strain genotype according 
to spoligotyping and IS6110 DNA fingerprinting.  
 
4.3.1 INH susceptible Beijing strain (K636) MIC (0.1µg/ml) 
QRT-PCR analysis of the INH susceptible Beijing strain showed no significant change in 
expression of 19 genes, whereas 5 genes (acpM, fabD, accD6, fbpC and iniB) were 
significantly regulated in response to 0.1µg/ml INH. Among the 5 up-regulated genes, four 
genes (acpM, fabD, accD6 and fbpC) were part of the MAP and one (iniB) gene was involved 
in drug transport. Additionally increased fold change was observed in genes that form part of 
the MAP (Table 4.3). 
 
4.3.2 INH mono-resistant Beijing strain (R55) MIC (4µg/ml) 
Analysis of the INH mono-resistance isolate showed significant up-regulation in 8 of the 
genes (ahpC, acpM, fabD, accD6, efpA, iniA, iniB, and Mmpl7) and a significant down-
regulation in 2 genes (ndh and fbpC) in response to 0.1 µg/ml INH. Four of the up-regulated 
genes (ahpC, acpM, fabD, and accD6) and 2 of the down-regulated genes (ndh and fpbC) 
formed part of the mycolic acid pathway, while 4 of the up-regulated genes (efpA, iniA, iniB 
and mmpl7) were involved in drug transport. Furthermore significant increase in genes 
expression was observed in genes involved in drug transport (Table 4.3). 
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Table 4.3: Differential expression profile of genes involved in the mycolic acid pathway and 
involved in drug transport after exposure to INH. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Legend to table 4.3: Fold change after 24hrs exposure to 0.1µg/ml INH where > 5 fold change was considered 
significant, # significant down-regulation, *significant up-regulation 
 
Figure 4.4 and 4.5, shows a summarized QRT-PCR analysis results of significantly regulated 
selected candidate genes from the MAP and drug transport after 24hrs exposure to 0.1µg/ml 
INH in INH susceptible and INH mono-resistance with no INH gene associated mutation 
 
 
 INH susceptible (K636) INH mono-resistant (R55) 
Genes Fold change Fold change 
Mycolic acid pathway genes 
katG 1.1 2.6 
furA 1.6 3.9 
ahpC 2.5 9.8* 
ndh 1.1 -10.6#  
InhA 1.0 2.2 
acpM 26.9* 6.5* 
kasA 1.7 2.1 
fas 1.7 2.1 
plsB 1.8 2.2 
fabD 7.5* 9.7* 
fadE -1.1 2.3 
accD6 14.8* 6* 
Pks13 1.6 3.2 
fbpC 12.5* -8# 
Drug transport genes 
efpA 2.9 15.8* 
iniA 2.5 11.3* 
iniB 5* 26* 
Mmpl7 1.2 5.1* 
pstB 2.8 2.1 
Rv1258c 2.9 2.7 
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Figure 4.4: Differential gene expression of selected candidate genes after 24hrs INH exposure 
Legend to figure 4.4: mRNA expression levels of selected genes in the mycolic acid pathway and drug transport genes in an INH susceptible Beijing strain (INH MIC 
0.1µg/ml) after exposure to 0.1µg/ml INH. * denotes > 5 fold change = significantly differentially expressed genes 
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Figure 4.5 Differential gene expressions of selected candidate genes after 24hrs INH exposure 
Legend to figure 4.5: mRNA expression levels of selected genes in the mycolic acid pathway and drug transport genes in INH mono resistant Beijing strain (INH MIC 
4µg/ml) after exposure to 0.1µg/ml INH. * denotes > 5 fold change = significantly differentially expressed genes
56 
 
 
 
Discussion 
 
In this study we selected candidate genes from the MAP, selection of these genes allowed 
investigation of other genes within the pathway that might be involved in resistance of INH. The 
MAP genes selected fell into three categories the FAS-I and FAS-II complexes and the final 
condensation step, without which mycolic acids needed for the survival of the bacterium cannot 
be synthesized. Additionally, drug transport genes which have been shown to respond to INH 
treatment were also selected to allow analysis of transport genes as an additional protective 
mechanism against INH toxicity (8,13,19,31,42).  
  
Exposure of the susceptible strain to INH (0.1µg/ml) resulted in a significant up-regulation in the 
expression of five genes (acpM, fabD, accD6, fbpC and iniB), three of the genes belong to the 
operon-like cluster (accD6, fabD, kasA, kasB and acpM) encoded by kas are involved in 
extension of meromycolates from FAS-I complex (24,29). It has been shown that inhibition of 
NADH-dependent enoyl-acyl-carrier-protein (InhA) by INH causes accumulation of mycolates 
and subsequent up-regulation in the expression of these genes (42). The other expressed gene 
(fbpC) has been implicated in export of proteins that catalysis maturation of mycolic acid in cell 
wall (35,43) and iniB which is a INH inducible genes (1).  
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QRT-PCR analysis of the selected candidate genes demonstrated a significant change in 
expression of genes involved in drug transport in INH mono-resistance strain when exposed to 
INH (0.1µg/ml). This indicates the bacterium intracellular regulation of INH which might be 
vital for the survival of the bacterium. Additionally a significant down regulation of ndh gene 
was observed indicating inefficient formation of the NAD+ substrate required for the complex 
formation with activated INH which results in shielding of InhA from the INH-NAD complex 
inhibition. 
 
Collectively these QRT-PCR results show that there are differences in genes expressed within 
the MAP and drug transport genes between the two Beijing isolates after treatment with low INH 
concentration. For instance, exposure to INH seems to increase expression of MAP genes in the 
susceptible isolate when compared to the resistant isolate, whereas the transport genes are 
significantly regulated in the resistance isolates. Furthermore it appears that there is a direct 
relation in the balance of NAD+ substrate required for complex formation with INH and 
activation of transport genes in the resistance isolate, which might be an additional protective 
mechanism for the bacterium (Figure 4.4 and 4.5). Based on these observations the following 
models were proposed for the effect of INH in INH susceptible and INH mono-resistant Beijing 
strains, respectively. 
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Killing mode of INH in the INH susceptible Beijing isolate 
INH enters the cell by passive diffusion where it becomes activated by catalase peroxidase 
encoded by the katG gene (3,17). During the INH activation process reactive oxygen species are 
formed and the catalase peroxidase on its own is not sufficient to detoxify this reactive oxygen 
species (40). This imbalance is sensed by the organism resulting in an increase in the synthesis of 
AhpC, thereby resulting in an increased expression of the ahpC gene which assists with 
detoxification of reactive oxygen species from the cell (35). 
 
The activated INH forms a complex with NAD which targets the inhA protein, thus blocking the 
FAS-II complex resulting in the accumulation of fatty acid (36). The imbalance in mycolic acid 
biosynthesis is in turn is sensed by these (acpM-kasA, fabD and accD6) proteins followed by the 
increase expression of their respective genes (29,42). Furthermore up-regulation of fbpC gene 
due to INH induction is indicative of inhibition of mycolic acid synthesis. Gene expression might 
be as result of a feedback mechanism that senses the depletion of mature mycolates resulting in 
the death of the bacterium (42) (Figure 4.6). 
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Figure 4.6: Killing mode of sub-lethal concentration of INH in the susceptible Beijing isolate, 
INH MIC (0.1µg/ml) 
  
 
 
 
Mode of INH action in INH mono-resistant Beijing isolate with no associated gene  
mutations 
 
In the resistant strain, INH enters the cell by passive diffusion where it becomes activated by 
catalase peroxidase encoded by the katG gene (3,17). Similarly to the sensitive strain activation 
Legend to 4.6:    Denotes up-regulation of genes,        denotes reaction inhibition 
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of INH forms reactive oxygen species and the catalase peroxidase on its own is not sufficient to 
detoxify this reactive species (40). This imbalance is sensed by the organism resulting in an 
increase in the synthesis of AhpC, thereby resulting in an increased expression of the ahpC gene 
which assists with detoxification of reactive oxygen species from the cell (42). 
 
Significant down-regulation of ndh gene which encodes NADH dehydrogenase was also 
observed. During the INH activation process NADH dehydrogenase catalysis the conversion of 
NADH to NAD+ required for complex formation with the active INH (38). The repressed 
expression of this gene implies inefficient NAD+ substrate formation which causes imbalance in 
intracellular NADH/NAD+ ratio (38). As a result of this intracellular NADH level  increases and 
acts as a competitive inhibitor to InhA binding, thereby protecting InhA against inhibition by the 
INH-NAD complex (6,38). At the same time the activated INH results in expression of the drug 
transporting genes (efpA, iniA, iniB and Mmpl7) which causes pumping out of the active INH 
from the cell, therefore preventing inhibition of the InhA from the INH-NAD complex (Figure 
4.7). 
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Figure 4.7: Mode of INH action in INH mono-resistant Beijing isolate with no INH gene 
associated mutations, INH MIC (4µg/ml) 
 
 
 
Legend to 4.7:    Denotes up-regulation of genes,    denotes down-regulation of genes,     denotes inhibition of reaction 
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Figure 4.8, indicates the difference in gene expression observed in the two models. The arrows 
denote expression of genes for the respective isolates. The gene profile of the susceptible isolate 
signifies killing mechanism, whereas the mono-resistant isolate presents resistant mechanism. 
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Figure 4.8: Difference observed in gene expression between the two isolates 
Legend to 4.8: Genes expressed in INH mono-resistant isolate   , Genes expressed in INH susceptible isolate 
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Chapter 5 
 
CONCLUSION 
 
 
Previous microarray studies done on H37Rv and other resistant clinical isolates have reported 
regulation of various genes after exposure to different concentrations of INH (1-3,5,6). Number 
of these genes were revealed to encode the FAS-II complex and others to mediated the toxic 
affect of INH (2-4,6). This study correlates with what has been previously reported in literature, 
except for the difference in the expression pattern observed in fbpC gene between the two 
isolates and the significant down-regulation of ndh gene as a result of INH exposure. In addition 
this study has shown that the transcriptomics analysis of INH susceptible and INH mono-
resistant Beijing isolates revealed various differentially expressed genes in response to low 
concentrations of INH in both the MAP and drug transport.  
 
The response to INH suggests that expression profiles presented provides characteristic that is 
specific for the cellular process that is affected by INH and gene expression profile observed in 
the susceptible isolate is indicative of the inhibition of FAS-II complex indicating death of the 
bacterium. The proposed model whereby the bacterium compensate for INH toxicity indicate 
that clinical Mycobacterium tuberculosis isolates resistant to INH which do not have genomic 
mutations might use efflux related mechanism in combination with  imbalance in intracellular 
NADH/NAD+ ratio to prevent inhibition of InhA by INH-NAD complex, thereby allowing the 
bacterium to acquire additional resistance. However we do acknowledge that our cohort had 
limitations in that there might be genes from other pathways that directly or indirectly play a role 
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in INH resistance. Therefore further studies are necessary to test the proposed model which 
might give a novel insight into the mechanism whereby Mycobacterium tuberculosis is capable 
of evading INH toxicity. 
 
Future studies needed to test our proposed model: 
 
1. Whole genome sequencing analysis of the two isolates in order to understand the 
complete mechanism of INH in clinical isolates that do not present mutations in the five 
gene associated with INH 
 
2. RNA sequencing analysis which will enable us to generate an unprecedented global view 
of the transcriptome between the two strains thus helping us to understand the 
transcriptome dynamics under INH induction of the selected strains. 
 
3. Utilizing Proteomics to investigate the selected isolate which might reflect the functional 
importance of a cell in response to INH. 
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ADDENDA 
 
Technical issues encounted during the study 
 
1. Culture growth contamination 
 
Solution 
  
 All bacterial inoculation was performed in the bio-safety level 3 labs and sterile tissue 
culture flasks were used. 
 Media used was autoclaved and filtered  before use 
 Culture flasks were wiped with incidin on the outside before storage 
 OD measurements were taken once a week and only filtered tips were used 
 
 
2. Difficulty in RNA extraction (DNA contamination, Degraded RNA, Low RNA 
quantity) 
 
Solution 
 
 Wearing gloves all the time and using RNase wipe to clean  all surface 
 Using separate stock of chemicals for RNA work 
 Filtered RNase free tips  and pre packed RNase free materials were used 
 Standard PCR was performed using isolated RNA as template to insure  that there 
was no DNA contamination  
 Although is virtually impossible to completely eliminate genomic DNA a Minus 
RT control was also used as an additional control  
 
 
3. poor primer design (primer dimers) 
Solution 
 
 
 Primer design software was used for primers design which included adjustable parameters  
  This was followed up by assay validation where the primer pairs were tested in all 
combination with probe and known template (cDNA) 
 Primers that gave the lowest CT and the highest ΔRn were used 
  
  Amplicons were identified by melting curves 
 
 
 
